In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk

被引：2
|
作者：
Ali, Hyeon-Ju [1 ]
Deswal, Anita [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2023年 / 176卷 / 12期
关键词：
D O I：
10.7326/J23-0101
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Source Citation Kosiborod MN, AbildstrOm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069-1084. 37622681 Clinical Impact Ratings GIM/FP/GP: Cardiology:
引用
收藏
页码：JC136 / JC136
页数：1
相关论文
共 50 条
  • [21] Reduced energy intake or increased physical activity? Effective weight-loss strategies for women
    Kirkwood, L.
    Aldujaili, E.
    Drummond, S.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2005, 64 : 57A - 57A
  • [22] Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial
    Kosiborod, Mikhail N.
    Verma, Subodh
    Borlaug, Barry A.
    Butler, Javed
    Davies, Melanie J.
    Jensen, Thomas Jon
    Rasmussen, Soren
    Marstrand, Peter Erlang
    Petrie, Mark C.
    Shah, Sanjiv J.
    Ito, Hiroshi
    Schou, Morten
    Melenovsky, Vojtech
    Abhayaratna, Walter
    Kitzman, Dalane W.
    CIRCULATION, 2024, 149 (03) : 204 - 216
  • [23] COST-EFFECTIVENESS OF TIRZEPATIDE VERSUS SEMAGLUTIDE (BOTH ADJUNCT TO A REDUCED-CALORIE DIET AND INCREASED PHYSICAL ACTIVITY) IN PATIENTS WITH OBESITY OR OVERWEIGHT FROM A UK PERSPECTIVE
    Capehorn, M.
    Johansson, E.
    Davies, A. L.
    Evans, J.
    Godbeer, F.
    Van, Hest N.
    Cotterill, G.
    Tolley, K.
    VALUE IN HEALTH, 2024, 27 (12) : S77 - S77
  • [24] Effects of physical activity on depressive symptoms and weight loss in patients undergoing bariatric surgery
    Kose, Melisa
    Kose, Melisa
    McLaughlin, Anna Patricia
    Mariani, Nicole
    Milton, Rebecca
    Lombardo, Giulia
    Malys, Mantas
    Zajowska, Zuzanna
    Mondelli, Valeria
    PSYCHONEUROENDOCRINOLOGY, 2024, 160
  • [25] In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly ER exenatide
    Bekiari, Eleni
    Karagiannis, Thomas
    Tsapas, Apostolos
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (08) : JC46 - JC46
  • [26] OBESITY IS ASSOCIATED WITH INCREASED POST-PRANDIAL GIP LEVELS WHICH ARE NOT REDUCED BY DIETARY RESTRICTION AND WEIGHT-LOSS
    JONES, IR
    OWENS, DR
    LUZIO, SD
    HAYES, TM
    DIABETES & METABOLISM, 1989, 15 (01) : 11 - 22
  • [27] Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
    Able, Corey
    Liao, Brian
    Saffati, Gal
    Maremanda, Ankith
    Applewhite, James
    Nasrallah, Ali A.
    Sonstein, Joseph
    Alzweri, Laith
    Kohn, Taylor P.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2024,
  • [28] Psychiatric symptoms, substance use, and other medical conditions in patients with obesity who seek treatment for weight loss
    Marin-Navarrete, Rodrigo
    Quintero, Javier
    Correas-Lauffer, Javier
    Cortes-Ramirez, Julio
    Villalobos-Gallegos, Luis
    SALUD MENTAL, 2016, 39 (03) : 109 - 116
  • [29] Intrahepatic Fat, Not Obesity, Is a Main Driver of the Metabolic Syndrome in Obese Patients and Is Significantly Reduced by Weight Loss Surgery
    Khoraki, Jad
    Wiens, Curtis N.
    McMillan, Alan B.
    Artz, Nathan S.
    Haufe, William
    Campo, Camilo A.
    Schlein, Alexandria
    Sirlin, Claude B.
    Reeder, Scott B.
    Campos, Guilherme M.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : E1 - E1
  • [30] Comment on: Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
    Unal, Selman
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2024,
12345